Hikma Full Year 2010 Results Show Promise

Furthermore, we note that while Hikma is heavily exposed to the unrest in the MENA region, the company is attempting to increase its presence in the US and diversify its portfolio to include high-value molecules. In November 2010, Hikma announced the acquisition of multinational drugmaker Baxter Healthcare's US multi-source generic injectables (genectables) business for US$112mn, catapulting Hikma from the tenth- to the second-largest injectables supplier in the US drug market, with a 15% market share.

To read the full article, please choose one of the following options: